氨甲酰化促红细胞生成素在慢性肾脏病基础上急性肾损伤及其他急性肾损伤模型中的疗效优于促红细胞生成素
研究在大鼠模型中比较相同剂量的促红细胞生成素(EPO)与氨甲酰化促红细胞生成素(CEPO)对缺血再灌注所致急性肾损伤(AKI)的肾脏保护、血流动力学、血液学及生存影响。结果显示CEPO在改善肾功能、体重和生存方面优于EPO,且血细胞比容和收缩压升高幅度更小。
要点
- 在慢性肾脏病基础上急性肾损伤大鼠中,CEPO较EPO更改善肾功能和体重,血细胞比容升高更小,生存改善相似。
- 在其他急性肾损伤模型中,CEPO较EPO更改善肾功能保护与恢复及生存,收缩压和血细胞比容升高更小。
- 老年或雄性动物较年轻或雌性动物肾功能损失更重、死亡率更高。
核心结论
- CEPO可改善急性肾损伤模型的肾功能、体重和肾脏重量及生存,且不似EPO那样显著升高血细胞比容和血压。
- 作者认为CEPO治疗在改善常见临床急性肾损伤结局方面可能优于EPO。
研究设计与样本
- 研究在大鼠急性肾损伤模型中进行,包括慢性肾脏病基础上叠加缺血再灌注所致急性肾损伤(5000 U/kg EPO或CEPO,皮下注射三次)。
- 还包括老年与年轻、雄性雌性动物的缺血再灌注所致急性肾损伤(1000 U/kg EPO或CEPO,皮下注射三次)。
主要发现
- 在慢性肾脏病基础上急性肾损伤动物中,与EPO治疗相比,CEPO治疗引起更大的肾功能和体重改善,血细胞比容升高更小,生存改善相似。
- 在其他急性肾损伤组中,与EPO治疗相比,CEPO治疗引起更大的肾功能保护和恢复及生存改善,收缩压和血细胞比容升高更小。
- 总体而言,老年或雄性动物分别较年轻或雌性动物有更严重的肾功能损失和更高的死亡率。
- mRNA和蛋白表达分析证实肾脏表达异二聚体EPO受体/CD131复合物,这是CEPO信号发挥组织保护作用所必需的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Erythropoietin (EPO) may be a beneficial tissue-protective cytokine. However, high doses of EPO are associate with adverse effects, including thrombosis, tumor growth, and hypertension. Carbamylated erythropoietin (CEPO) lacks both erythropoietic and vasoconstrictive actions. In this study, we compared the renoprotective, hemodynamic, and hematologic activities and survival effects of identical EPO and CEPO doses in rat models of clinically relevant AKI presentations, including ischemia-reperfusion-induced AKI superimposed on CKD (5000 U/kg EPO or CEPO; three subcutaneous injections) and ischemia-reperfusion-induced AKI in old versus young animals and male versus female animals (1000 U/kg EPO or CEPO; three subcutaneous injections). Compared with EPO therapy, CEPO therapy induced greater improvements in renal function and body weight in AKI on CKD animals, with smaller increases in hematocrit levels and similarly improved survival. Compared with EPO therapy in the other AKI groups, CEPO therapy induced greater improvements in protection and recovery of renal function and survival, with smaller increases in systolic BP and hematocrit levels. Overall, old or male animals had more severe loss in kidney function and higher mortality rates than young or female animals, respectively. Notably, mRNA and protein expression analyses confirmed the renal expression of the heterodimeric EPO receptor/CD131 complex, which is required for the tissue-protective effects of CEPO signaling. In conclusion, CEPO improves renal function, body and kidney weight, and survival in AKI models without raising hematocrit levels and BP as substantially as EPO. Thus, CEPO therapy may be superior to EPO in improving outcomes in common forms of clinical AKI.
引用
- Tögel FE, Ahlstrom JD, Yang Y, et al. Carbamylated Erythropoietin Outperforms Erythropoietin in the Treatment of AKI-on-CKD and Other AKI Models. J Am Soc Nephrol. 2016. PMID: 26984884
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。